You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

61 search results for: biologics

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
View more
Prurigo Nodularis: The Patient Journey
interactivity

Prurigo Nodularis: The Patient Journey

Dermatology
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
View more
UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications
expert video

UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications

Dermatology
Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.
View more
2022: EoE Year in Review
expert video

2022: EoE Year in Review

Gastroenterology
Join Dr. Ikuo Hirano for an informative review of the key scientific advances in EoE from 2022
View more
ESPGHAN 2024 | Clinical Management of Young Children With EoE
expert video

ESPGHAN 2024 | Clinical Management of Young Children With EoE

Gastroenterology
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.
View more
New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management
expert video

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

Dermatology
Review the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies.
View more
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Pulmonology
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
View more
ERS 2024 | IL-33 A Promising Target
expert video

ERS 2024 | IL-33 A Promising Target

Pulmonology
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
View more
Emerging Therapeutic Landscape and Implications for Patient Management in CSU
expert video

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

Dermatology
A review of disease burden and treatment needs in CSU, and how current and emerging therapies can impact patient management.
View more
EAACI 2023 | What is New in the Treatment of Children
expert video

EAACI 2023 | What is New in the Treatment of Children

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: The NetherlandsChange country/region